Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Phxa34
2. Phxa41
3. Xalatan
1. 130209-82-4
2. Xalatan
3. Phxa41
4. Phxa-41
5. Xa41
6. Phxa 41
7. Xa-41
8. Latanoprost (isopropyl Ester)
9. Isopropyl (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((3r)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
10. Propan-2-yl (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
11. Latanoprost, (+/-)-
12. 6z5b6hvf6o
13. 8s5fb3xxg8
14. Latanoprost, Ethanol Solution
15. Chebi:6384
16. Propan-2-yl (5z)-7-{(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
17. T-2345
18. T2345
19. 5-heptenoic Acid, 7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl Ester, (5z)-
20. Isopropyl (5z,9alpha,11alpha,15r)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate
21. Catioprost
22. (z)-isopropyl 7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((r)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate
23. 155551-81-8
24. 5-heptenoic Acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl Ester
25. Smr000466354
26. Xalatan (tn)
27. Unii-6z5b6hvf6o
28. Latanoprostum
29. Nova-21027
30. Latanoprost [usan:inn:ban]
31. Xa 41
32. Phxa34 [as 15(r,s)-isomer]
33. Propan-2-yl (5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
34. Ar-202
35. Mfcd00216074
36. Xelpros
37. L-ppds
38. Latanoprost [mi]
39. Latanoprost [inn]
40. Latanoprost [jan]
41. Latanoprost [usan]
42. Unii-8s5fb3xxg8
43. Latanoprost [vandf]
44. Chembl1051
45. Latanoprost [mart.]
46. Schembl24698
47. Latanoprost [usp-rs]
48. Latanoprost [who-dd]
49. Mls000759468
50. Mls001424106
51. Latanoprost (jan/usp/inn)
52. Gtpl1961
53. Dtxsid1041057
54. Latanoprost [orange Book]
55. Hms2051h11
56. Hms2089j17
57. Hms3715n22
58. Latanoprost [ep Monograph]
59. Latanoprost [usp Monograph]
60. Amy30089
61. Ex-a1770
62. Hy-b0577
63. Xalacom Component Latanoprost
64. Bdbm50240648
65. S4709
66. Zinc12468792
67. Latanoprost, >=98% (hplc), Oil
68. Rocklatan Component Latanoprost
69. Akos024458331
70. Ccg-100946
71. Db00654
72. Nc00196
73. Latanoprost Component Of Rocklatan
74. Ncgc00246969-01
75. Ncgc00246969-06
76. (5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptanoic Acid 1-methylethyl Ester
77. As-75099
78. L0262
79. D00356
80. Ab00640005-04
81. Ab00640005-06
82. 209l824
83. A806039
84. Q634959
85. Sr-01000759428
86. J-005764
87. Sr-01000759428-4
88. Latanoprost, United States Pharmacopeia (usp) Reference Standard
89. Tris(2,4-dimethylphenyl)phosphine-5,5',5""""-trisulfonic Acid Trisodium Salt
90. (1r,2r,3r,5s,3''r)-7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pentyl)-cyclopentyl]-hept-5-enoic Acid Isopropyl Ester
91. (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic Acid Propan-2-yl Ester
92. 5-heptenoic Acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl Ester, (1r-(1-alpha(z),2-beta(r*),3-alpha,5-alpha))-
93. 5-heptenoic Acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-1-methylethyl Ester, (1r-(1.alpha.(z),2.beta.(r*),3.alpha.,5.alpha.))-
94. Isopropyl (5z,9alpha,11alpha,15r)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate;xalatan
95. Propan-2-yl (z)-7-[(1r,2r,3r,5s)-3,5-bis(oxidanyl)-2-[(3r)-3-oxidanyl-5-phenyl-pentyl]cyclopentyl]hept-5-enoate
| Molecular Weight | 432.6 g/mol |
|---|---|
| Molecular Formula | C26H40O5 |
| XLogP3 | 4.3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 14 |
| Exact Mass | 432.28757437 g/mol |
| Monoisotopic Mass | 432.28757437 g/mol |
| Topological Polar Surface Area | 87 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 526 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Latanoprost |
| PubMed Health | Latanoprost (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | Latanoprost is a prostaglandin F2 analogue. Its chemical name is isopropyl-(Z)-7[(1R,2R,3R,5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate. Its molecular formula is C26H40O5 and its chemical structure is:Latanoprost is a... |
| Active Ingredient | Latanoprost |
| Dosage Form | Solution/drops; Solution |
| Route | Ophthalmic; ophthalmic |
| Strength | 0.005% |
| Market Status | Tentative Approval; Prescription |
| Company | Alcon Res; Par Pharm; Bausch And Lomb; Luitpold; Dr Reddys Labs; Mylan; Akorn |
| 2 of 4 | |
|---|---|
| Drug Name | Xalatan |
| PubMed Health | Latanoprost (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | Latanoprost is a prostaglandin F2 analogue. Its chemical name is isopropyl-(Z)-7[(1R,2R,3R,5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate. Its molecular formula is C26H40O5 and its chemical structure is:Latanoprost is a... |
| Active Ingredient | Latanoprost |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.005% |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
| 3 of 4 | |
|---|---|
| Drug Name | Latanoprost |
| PubMed Health | Latanoprost (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | Latanoprost is a prostaglandin F2 analogue. Its chemical name is isopropyl-(Z)-7[(1R,2R,3R,5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate. Its molecular formula is C26H40O5 and its chemical structure is:Latanoprost is a... |
| Active Ingredient | Latanoprost |
| Dosage Form | Solution/drops; Solution |
| Route | Ophthalmic; ophthalmic |
| Strength | 0.005% |
| Market Status | Tentative Approval; Prescription |
| Company | Alcon Res; Par Pharm; Bausch And Lomb; Luitpold; Dr Reddys Labs; Mylan; Akorn |
| 4 of 4 | |
|---|---|
| Drug Name | Xalatan |
| PubMed Health | Latanoprost (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | Latanoprost is a prostaglandin F2 analogue. Its chemical name is isopropyl-(Z)-7[(1R,2R,3R,5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate. Its molecular formula is C26H40O5 and its chemical structure is:Latanoprost is a... |
| Active Ingredient | Latanoprost |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.005% |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
Latanoprost is indicated for the reduction of elevated intraocular pressure in patients who have been diagnosed with open-angle glaucoma or ocular hypertension. Latanoprost may be combined in a product with [Netarsudil], a rho kinase inhibitor, for the same indications. In addition to the above indications, the Canadian monograph for this drug also approves latanoprost for the treatment of elevated intraocular pressure as a result of angle-closure glaucoma that has been treated with peripheral iridotomy or laser iridoplasty.
FDA Label
Treatment of glaucoma
Latanoprost effectively decreases intraocular pressure by increasing uveoscleral outflow. A decrease in intraocular pressure has been measured within 34 hours post-administration, reaches a maximum decrease at 812 hours, and can be maintained for a period of 24 hours. **A note on eye and periorbital changes** Between 3 to 10% of patients taking latanoprost have experienced iris pigmentation after about 3-4 months of latanoprost use. Patients should be notified of this risk before initiating treatment. It may occur in both patients with light-colored irides (green-brown or blue/grey-brown) or dark-colored (brown) irides, but is less pronounced in the latter group. This drug may also cause other ocular effects including infrequent conjunctival hyperemia, pigmentation of periocular tissues, eyelash changes, hypertrichosis, and ocular irritation.
Ophthalmic Solutions
Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS. (See all compounds classified as Ophthalmic Solutions.)
S01EE01
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
S - Sensory organs
S01 - Ophthalmologicals
S01E - Antiglaucoma preparations and miotics
S01EE - Prostaglandin analogues
S01EE01 - Latanoprost
Absorption
This drug is rapidly absorbed in the cornea as an isopropyl ester prodrug and is then activated by the process of hydrolysis. A small amount of this drug is systemically absorbed. The Cmax of latanoprost in the systemic circulation is reached after 5 minutes and is measured to be 53 pg/mL. The Cmax in the aqueous humor is attained within 2 hours after administration. and has been estimated to be 15-30 ng/mL.
Route of Elimination
After hepatic beta-oxidation, the metabolites of latanoprost are primarily found to be excreted by the kidneys. About 88% of the latanoprost dose is recovered in the urine after topical administration. About 15% of a dose is reported to be excreted in the feces.
Volume of Distribution
The volume of distribution of latanoprost is 0.16 0.02 L/kg. The activated acid form of latanoprost can be measured in aqueous humor in the initial 4 hours post-administration, and it is measured in the plasma only for 1 hour following ophthalmic administration. This drug is more lipophilic than its parent prostaglandin and easily penetrates the cornea. It has been shown to cross the placenta in rats.
Clearance
The systemic clearance of latanoprost is 7 mL/min/kg.
After corneal uptake, this prodrug is hydrolyzed and activated by esterases to become a pharmacologically active drug. The small portion of this drug that is able to reach the circulation is found to be metabolized by the liver to the 1,2-dinor and 1,2,3,4-tetranor metabolites through fatty acid beta-oxidation.
The elimination half-life of latanoprost from the plasma is about 17 minutes. The elimination half-life of latanoprost from the eye is estimated at 23 hours.
Elevated intraocular pressure leads to an increased risk of glaucomatous visual field loss. The higher the intraocular pressure, the higher the risk of damage to the optic nerve and loss of visual field. Latanoprost selectively stimulates the prostaglandin F2 alpha receptor and this results in a decreased intraocular pressure (IOP) via the increased outflow of aqueous humor, which is often implicated in cases of elevated intraocular pressure. Possible specific mechanisms of the abovementioned increased aqueous outflow are the remodeling of the extracellular matrix and regulation of matrix metalloproteinases. These actions result in higher tissue permeability related to humor outflow pathways, which likely change outflow resistance and/or outflow rates.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - SOLUTION/DROPS;OPHTHALMIC - 0.005%
USFDA APPLICATION NUMBER - 20597
DOSAGE - EMULSION;OPHTHALMIC - 0.005%
USFDA APPLICATION NUMBER - 206185
Related Excipient Companies
Excipients by Applications
Parenteral
Solubilizers
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
11
PharmaCompass offers a list of Latanoprost API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Latanoprost manufacturer or Latanoprost supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Latanoprost manufacturer or Latanoprost supplier.
PharmaCompass also assists you with knowing the Latanoprost API Price utilized in the formulation of products. Latanoprost API Price is not always fixed or binding as the Latanoprost Price is obtained through a variety of data sources. The Latanoprost Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Latanoprost manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Latanoprost, including repackagers and relabelers. The FDA regulates Latanoprost manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Latanoprost API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Latanoprost manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Latanoprost supplier is an individual or a company that provides Latanoprost active pharmaceutical ingredient (API) or Latanoprost finished formulations upon request. The Latanoprost suppliers may include Latanoprost API manufacturers, exporters, distributors and traders.
click here to find a list of Latanoprost suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Latanoprost DMF (Drug Master File) is a document detailing the whole manufacturing process of Latanoprost active pharmaceutical ingredient (API) in detail. Different forms of Latanoprost DMFs exist exist since differing nations have different regulations, such as Latanoprost USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Latanoprost DMF submitted to regulatory agencies in the US is known as a USDMF. Latanoprost USDMF includes data on Latanoprost's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Latanoprost USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Latanoprost suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Latanoprost Drug Master File in Japan (Latanoprost JDMF) empowers Latanoprost API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Latanoprost JDMF during the approval evaluation for pharmaceutical products. At the time of Latanoprost JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Latanoprost suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Latanoprost Drug Master File in Korea (Latanoprost KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Latanoprost. The MFDS reviews the Latanoprost KDMF as part of the drug registration process and uses the information provided in the Latanoprost KDMF to evaluate the safety and efficacy of the drug.
After submitting a Latanoprost KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Latanoprost API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Latanoprost suppliers with KDMF on PharmaCompass.
A Latanoprost CEP of the European Pharmacopoeia monograph is often referred to as a Latanoprost Certificate of Suitability (COS). The purpose of a Latanoprost CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Latanoprost EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Latanoprost to their clients by showing that a Latanoprost CEP has been issued for it. The manufacturer submits a Latanoprost CEP (COS) as part of the market authorization procedure, and it takes on the role of a Latanoprost CEP holder for the record. Additionally, the data presented in the Latanoprost CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Latanoprost DMF.
A Latanoprost CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Latanoprost CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Latanoprost suppliers with CEP (COS) on PharmaCompass.
A Latanoprost written confirmation (Latanoprost WC) is an official document issued by a regulatory agency to a Latanoprost manufacturer, verifying that the manufacturing facility of a Latanoprost active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Latanoprost APIs or Latanoprost finished pharmaceutical products to another nation, regulatory agencies frequently require a Latanoprost WC (written confirmation) as part of the regulatory process.
click here to find a list of Latanoprost suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Latanoprost as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Latanoprost API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Latanoprost as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Latanoprost and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Latanoprost NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Latanoprost suppliers with NDC on PharmaCompass.
Latanoprost Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Latanoprost GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Latanoprost GMP manufacturer or Latanoprost GMP API supplier for your needs.
A Latanoprost CoA (Certificate of Analysis) is a formal document that attests to Latanoprost's compliance with Latanoprost specifications and serves as a tool for batch-level quality control.
Latanoprost CoA mostly includes findings from lab analyses of a specific batch. For each Latanoprost CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Latanoprost may be tested according to a variety of international standards, such as European Pharmacopoeia (Latanoprost EP), Latanoprost JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Latanoprost USP).
